Skip to main content
. 2016 Mar 29;6:23726. doi: 10.1038/srep23726

Figure 6. Forest plots of the included studies comparing symptomatic deep vein thrombosis (a) and symptomatic pulmonary embolism (b) in patients who received rivaroxaban and those who received enoxaparin.

Figure 6